3350 Stock Chart & Stats
€4.02
-€0.04(-1.25%)
At close: 4:00 PM EDT
€4.02
-€0.04(-1.25%)
Day’s Range― - ―
52-Week Range€1.64 - €4.26
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€178.97M
Enterprise Value€189.64M
Total Cash (Recent Filing)€189.98M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Nov 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding57,009,010
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.84Price Target Upside70.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageAn effectively debt-free balance sheet reduces near-term solvency pressure and avoids significant interest obligations. This gives management more financial flexibility to fund clinical development and strategic priorities, although it does not offset the company’s ongoing losses or cash consumption.
Experienced Oncology GovernanceAdding a director with global oncology, business development, and commercialization experience could strengthen strategic oversight as the company advances its antibody-drug conjugate portfolio. This governance upgrade may improve decision quality and support future development and partnering efforts.
Larger Equity BufferThe larger equity base provides a stronger capital buffer than in the prior period and can help support operations while the company develops its pipeline. It also offers some resilience against near-term financial strain, though persistent losses could erode this cushion over time.
Bears Say
No Current RevenueZero trailing-twelve-month revenue indicates that the business is not currently generating operating sales at a meaningful level. Without a functioning revenue stream, funding depends on existing resources or future financing, while commercial validation and the path to sustainable growth remain unproven.
Persistent Large LossesLarge recurring losses show that current operating costs remain well above revenue generation. Continued unprofitability can consume the equity base, limit strategic flexibility, and increase the amount of funding required before the company can establish a sustainable earnings model.
Accelerating Cash BurnHeavy and deteriorating cash burn means the company is not close to self-funding its operations or development activities. Persistent negative free cash flow raises reliance on external capital over time and can weaken financial flexibility if losses continue without revenue recovery.
Whitehawk Therapeutics News
3350 FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was €1.64 and its highest was €4.26 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is €178.97M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 29 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.178 earnings per share for the quarter, beating the consensus estimate of -€0.264 by €0.086.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 57,009,010 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -€0.178 in its last earnings report, beating expectations of -€0.264. Following the earnings report the stock price went down -0.578%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in DE:3350
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.84 (70.08% Upside)
€6.84 (70.08% Upside)
Blogger Sentiment
Bullish
DE:3350 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.21%
12-Months-Change
Fundamentals
Return on Equity
-53.89%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
3350 Stock 12 Month Forecast
Average Price Target
€6.84
▲(70.08% Upside)